Clinical Investigation of AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0]

Alcon Research409 enrolled

Overview

The purpose of this study is to compare the safety and efficacy of an investigational multifocal intraocular lens (IOL) to an FDA-approved monofocal IOL.

Participants 21 years and older in need of cataract extraction were consented and randomized in a 1:1 ratio at each investigative site to receive either the AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 \[SV25T0\] or the AcrySof® IQ Monofocal IOL Model SN60WF in both eyes. Each participant completed a preoperative examination of both eyes, implantation of IOL at the operative visit for each eye, and up to 7 postoperative visits, with monocular testing at Day 1-2, Day 7-14, and Day 30-60, and monocular and binocular testing at Day 120-180 following the second implantation. The first eye to be implanted was considered the primary eye. The second eye was implanted 7 and 30 days of the first. If the first eye was not implanted during surgery, the second eye was not eligible. If the second eye was not implanted during surgery, only the first eye was followed.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

409

Conditions

Cataracts

Interventions

AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]DEVICE

Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient

AcrySof® IQ Monofocal IOL Model SN60WFDEVICE

Monofocal IOL implanted for long-term use over the lifetime of the cataract patient

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of bilateral cataracts * Willing and able to complete all required postoperative visits * Calculated lens power within the available supply range * Planned cataract removal by phacoemulsification * Potential postoperative visual acuity of 0.2 logMAR or better in both eyes * Preoperative astigmatism less than 1.0 diopter * Clear intraocular media other than cataract in study eyes * Preoperative Best Corrected Distance Visual Acuity (BCDVA) worse than 0.2 logMAR * Able to undergo second eye surgery between 7 days and 30 days of the first eye surgery * Other protocol-defined inclusion criteria may apply Exclusion Criteria: * Previous refractive surgery * Inflammation or edema of the cornea * Optic nerve atrophy * Pregnancy * Current participation in another investigational drug or device study * Other protocol-defined exclusion criteria may apply

Outcomes

Primary Outcomes

Mean Photopic Monocular Distance Corrected VA (53 cm) at Day 120-180

Visual acuity (VA) was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, Early Treatment Diabetic Retinopathy Study (ETDRS) chart set at 53 centimeters (cm) on the nearpoint rod. VA was measured in logMAR (logarithm of the minimum angle of resolution), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.

Time frame: Day 120-180 from second eye implantation

Number of Cumulative and Persistent Adverse Events as Defined in IS EN ISO 11979-7:2006, up to Day 120-180

Cumulative and persistent adverse events were collected. This outcome measure was prespecified for the multifocal IOL.

Time frame: Day 0 first operative eye visit, up to Day 120-180 from second eye implantation

Photopic Contrast Sensitivity Without Glare at Day 120-180

Contrast sensitivity (ie, the ability to detect objects by distinguishing them from their background) was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 without a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.

Time frame: Day 120-180 from second eye implantation

Photopic Contrast Sensitivity With Glare at Day 120-180

Contrast sensitivity was assessed binocularly with the participant's best spectacle correction under photopic (bright) conditions at a distance of 8 feet at spatial frequencies of 3, 6, 12, and 18 cycles per degree (cpd) using the Vector Vision CSV 1000 with a glare source. Raw scores from contrast sensitivity testing were transformed to log units. Scores of (-1) were set to missing; hence, the mean measures may be overestimated and the variability measures may be underestimated. A higher numeric value represents better contrast sensitivity.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Mean Photopic Monocular Best Corrected Distance VA (4 m) at Day 120-180

VA was tested monocularly (each eye separately) using the correction obtained from the manifest refraction and 100% contrast, ETDRS charts at a distance of 4 meters. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.

Time frame: Day 120-180 from second eye implantation

Mean Photopic Monocular Distance Corrected Near VA at Standard Distance (40 cm) at Day 120-180

VA was tested monocularly (each eye separately) using the manifest refraction adjusted for optical infinity and the hand-held, 100% contrast, ETDRS chart set at 40 cm on the nearpoint rod. VA was measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on an ETDRS chart. A lower numeric value represents better visual acuity. This analysis was prespecified for the primary eye.

Time frame: Day 120-180 from second eye implantation

Overall Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180

Overall Spectacle Independence was rated using SILVER (Spectacle Independence Lens Vision Evaluation and Repurchase), a new patient reported outcome questionnaire. The participant was asked, "How often do you wear eyeglasses or contact lenses overall?"

Time frame: Day 120-180 from second eye implantation

Near Spectacle Independence Using SILVER Patient Reported Outcome (PRO) Questionnaire at Day 120-180

Near Spectacle Independence was rated using SILVER, a new patient reported outcome questionnaire. The participant was asked, "How often do you wear eyeglasses or contact lenses for seeing objects up close?"

Time frame: Day 120-180 from second eye implantation